• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

July 17, 2017

Ambien: Does This Popular Sleep Medication Turn People into Zombies?

Author(s):

Joshua Pirestani

The FDA warns that several considerations must be taken into account before using the popular insomnia medication.

When pharmaceutical manufacturer Sanofi developed Ambien (zolpidem), the goal was to come up with a drug to treat insomnia, a prevalent sleep disorder in the United States other parts of the world. While it was proven to be effective, its side effects should not be taken lightly, since people who use it can become "Ambien zombies." This was a term coined by Susan Chana Lask, the attorney who represented Ambien users for a class action suit against the drug manufacturer.

According to the CDC, there are between 50 and 70 million American adults who suffer from wakefulness disorders. That said, it is not surprising that quite a number of people take sleeping aid medications to tackle their sleep disorders. But despite its efficacy, this hypnotic drug is also considered potentially dangerous, not only for its addicting properties, but more importantly, for causing bizarre behaviors and turning people into Ambien zombies.

Ambien Overview

Categorized as a Schedule IV drug, Ambien is easily accessible since it can be prescribed and refilled without restriction. Approved in 1992 by the FDA, this medication instantly became one of the most popular options to fight insomnia. When it was introduced, it competed against Halcion, another sleep aid that was banned in some countries because of its adverse effects, including suicidal tendencies and addiction.

Ambien activates and binds the GABA neurotransmitter with receptors. As a result, it takes away the neuron activity that triggers insomnia. Consequently, the brain slows down and sleep immediately follows.

It became an instant hit among consumers, with Sanofi reaching sales up to $2 billion. When cheaper, generic zolpidem was introduced in 2007, it was also widely accepted as one of the most popular prescription drugs in the country.

Ambien Zombie Stories

As more people took Ambien to combat insomnia, numerous tragic events associated with this drug also grew in number. There have been unfortunate incidents reported and lawsuits filed as a result of the side effects from this sleep medication.

In 2009, a man who was said to have taken Ambien killed 8 people and was given 142 to 179 year prison sentence. There was also the case of,

Lindsey Schweigert, whose car collided with another vehicle after she was prescribed the sleeping aid. It was reported that Schweigert was not aware that the accident took place.

Rapper Eminem claimed that 5 years of his life was erased from his memory because of Ambien. Actor John Stamos also became dependent on the drug.

There was also a woman who ran over people in her car when she was supposed to be sleeping soundly after using the medication.

But perhaps, it was in 2006, when Patrick Kennedy was involved in a car accident related to his intake of Ambien, when the bizarre side-effects of the sleep-inducing drug caught the attention of the media and the nation. This subsequently resulted to a class action lawsuit against the drug for allegedly transforming users into Ambien zombies.

This resulted in the FDA ordering pharmaceutical companies that manufacture hypnotics to heighten the awareness of consumers about the effects of the drug in their warning labels. Also, in May 2016, the agency issued another order to lower the recommended dosage and for consumers not to drive or engage in other activities that will require them to stay awake a day after taking Zolpidem.

Joshua Pirestani is the president and founder of the

American Pharmacy Purchasing Alliance

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
1 KOL is featured in this series.
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
1 expert in this video
Related Content
Advertisement
X-ray image of kidneys with CKD -- Image credit: Crystal light | stock.adobe.com
July 2nd 2025

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Gillian McGovern, Associate Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
pores on the skin of the face. Cleansing the face skin - Image credit: Angelina | stock.adobe.com
July 2nd 2025

Study Examines How Vitamin C Shapes Skin Health Through TET-Mediated Demethylation

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Chronic headache, migraine | Image Credit: Serega | stock.adobe.com
July 2nd 2025

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

Danielle Valletti, Assistant Editor
3d illustration of the heart and lung
July 2nd 2025

Lung Transplant Recipients at High Risk of Secondary Lung Infections Post-Infection With SARS-CoV-2 Omicron Variant

Luke Halpern, Assistant Editor
Related Content
Advertisement
X-ray image of kidneys with CKD -- Image credit: Crystal light | stock.adobe.com
July 2nd 2025

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Gillian McGovern, Associate Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
pores on the skin of the face. Cleansing the face skin - Image credit: Angelina | stock.adobe.com
July 2nd 2025

Study Examines How Vitamin C Shapes Skin Health Through TET-Mediated Demethylation

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
Chronic headache, migraine | Image Credit: Serega | stock.adobe.com
July 2nd 2025

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

Danielle Valletti, Assistant Editor
3d illustration of the heart and lung
July 2nd 2025

Lung Transplant Recipients at High Risk of Secondary Lung Infections Post-Infection With SARS-CoV-2 Omicron Variant

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.